# GLP-1 Drugs Show Promise for Binge Eating Disorder
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) may reduce binge eating episodes and improve eating behaviors in people with binge eating disorder, emerging research suggests.
The medications work by slowing gastric emptying and affecting appetite-regulating hormones in the brain. These mechanisms appear to extend beyond weight loss to address the compulsive eating patterns that define binge eating disorder, a condition affecting millions of adults who experience recurrent episodes of consuming large amounts of food while feeling a loss of control.
A growing body of clinical experience and preliminary studies indicates that GLP-1 drugs reduce both the frequency and severity of binge episodes. Patients report feeling fuller longer and experiencing less intense urges to binge. The appetite suppression these drugs produce appears to interrupt the binge-restrict cycle that characterizes the disorder.
However, researchers emphasize that these medications are not a standalone treatment. Binge eating disorder involves complex psychological, behavioral, and neurological components. Cognitive behavioral therapy and dialectical behavior therapy remain the gold standard treatments. GLP-1 drugs show their greatest benefit when combined with therapeutic intervention and comprehensive eating disorder treatment.
Several considerations apply before using GLP-1 drugs for binge eating disorder. These medications carry their own risks, including gastrointestinal side effects and the potential for developing restrictive eating patterns if not carefully monitored. People with a personal or family history of thyroid cancer or multiple endocrine neoplasia should avoid these drugs. Additionally, the long-term effects remain unclear since these medications are relatively new for this indication.
Medical professionals treating eating disorders are beginning to investigate whether